Growth Prospects of the Schizophrenia - Pipeline Review, H2 2016

Schizophrenia - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Complete report available @ Schizophrenia - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 13, 30, 1, 53, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.Schizophrenia.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Adamed Sp. z o.o. Aequus Pharmaceuticals Inc. Aestus Therapeutics, Inc. AgeneBio Inc. Alkermes Plc Angita B.V. Astellas Pharma Inc. Athersys, Inc. Avanir Pharmaceuticals, Inc. Avineuro Pharmaceuticals, Inc. BCWorld Pharm Co. Ltd. BioCrea GmbH BioHealthonomics Inc Boehringer Ingelheim GmbH Braeburn Pharmaceuticals, Inc. Bristol-Myers Squibb Company Critical Pharmaceuticals Limited Curemark, LLC Delpor, Inc. Denovo Biopharma, LLC Echo Pharmaceuticals B.V. Egis Gyogyszergyar Nyrt Evotec AG F. Hoffmann-La Roche Ltd. Fabre-Kramer Pharmaceuticals, Inc. Galenea Corp. GeNeuro SA Glenmark Pharmaceuticals Ltd GP Pharm, S.A. GW Pharmaceuticals Plc H. Lundbeck A/S Heptares Therapeutics Limited Hisamitsu Pharmaceutical Co., Inc. Indivior Plc INSYS Therapeutics, Inc. Integrative Research Laboratories Sweden AB IntelGenx Corp. Intra-Cellular Therapies, Inc. Jiangsu Nhwa Pharmaceutical Corporation Ltd. Johnson & Johnson Karuna Pharmaceuticals Inc. KemPharm, Inc. Laboratorios Farmaceuticos Rovi, S.A. Lead Discovery Center GmbH Lohocla Research Corporation Luye Pharma Group Ltd. Mapi Pharma Ltd. Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation Neurocrine Biosciences, Inc. NeurOp, Inc Newron Pharmaceuticals S.p.A. Omeros Corporation Otsuka Holdings Co., Ltd. Peptron, Inc. Pfizer Inc. Promentis Pharmaceuticals, Inc. Ra Pharmaceuticals, Inc. Reviva Pharmaceuticals Inc. Richter Gedeon Nyrt. SK Biopharmaceuticals Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. Suven Life Sciences Ltd. Taisho Pharmaceutical Holdings Co., Ltd. Takeda Pharmaceutical Company Limited Tetra Discovery Partners LLC Teva Pharmaceutical Industries Ltd. Vanda Pharmaceuticals Inc. Vitality Biopharma Inc VLP Therapeutics, LLC Zogenix, Inc. Zysis Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###